We
prepared the condensed consolidated financial statements following the
requirements of the Securities and Exchange Commission (SEC) for interim
reporting. As permitted under those rules, certain footnotes or other financial
information that are normally required by accounting principles generally
accepted in the United States of America (U.S. GAAP) can be condensed or
omitted. Balance sheet amounts and operating results for subsidiaries operating
outside the U.S. are as of and for the three-month periods ended February 22,
2009, and February 24, 2008.
We made
certain reclassifications to prior-period amounts to conform to the
first-quarter 2009 presentation related to the presentation of noncontrolling
interests as a result of adopting a new accounting standard (See Note 2. Adoption of New Accounting
Policies.)
Revenues,
expenses, assets and liabilities can vary during each quarter of the year.
Therefore, the results and trends in these interim financial statements may not
be representative of those for the full year.
We are
responsible for the unaudited financial statements included in this
document. The financial statements include all normal and recurring
adjustments that are considered necessary for the fair presentation of our
financial position and operating results.
The
information included in this Quarterly Report on Form 10-Q should be read in
conjunction with the consolidated financial statements and accompanying notes
included in Pfizer s Annual Report on Form 10-K for the year ended December
31, 2008.
On January
26, 2009, we announced that we entered into a definitive merger agreement under
which we will acquire Wyeth in a cash-and-stock transaction valued on that date
at $50.19 per share, or a total of $68 billion. While we have taken actions and
incurred costs associated with the pending transaction that are reflected in our
financial statements, the pending acquisition of Wyeth will not be reflected in
our financial statements until consummation. (See Note 14. Pending Acquisition of
Wyeth.)
Note 2. Adoption of New
Accounting Policies
As of
January 1, 2009, we adopted Financial Accounting Standards Board (FASB)
Statement of Financial Accounting Standards (SFAS) No. 141R, Business Combinations, as
amended. SFAS 141R, as amended, retains the purchase method of accounting for
acquisitions, but requires a number of changes, including changes in the way
assets and liabilities are recognized in purchase accounting. It also changes
the recognition of assets acquired and liabilities assumed arising from
contingencies, requires the capitalization of in-process research and
development costs at fair value and requires the expensing of
acquisition-related costs as incurred. The adoption of SFAS 141R, as amended,
did not impact our consolidated financial statements upon adoption, but does
impact the accounting for future acquisitions, including our pending acquisition
of Wyeth.
As of
January 1, 2009, we adopted FASB Financial Staff Position (FSP) SFAS No. 142-3,
Determination of the Useful
Life of Intangible Assets. FSP SFAS 142-3 amends the factors considered
in developing renewal or extension assumptions used to determine the useful life
of a recognized intangible asset. Among other things, in the absence of
historical experience, an entity will be required to consider assumptions used
by market participants. The adoption of FSP SFAS 142-3 did not impact our
consolidated financial statements upon adoption, but could impact the accounting
for future acquisitions.
As of
January 1, 2009, we adopted the provisions of FASB SFAS No. 157, Fair Value Measurements, as
amended, that we did not adopt as of January 1, 2008. SFAS 157, as amended,
defines fair value, expands related disclosure requirements and specifies a
hierarchy of valuation techniques based on the nature of the inputs used to
develop the fair value measures. The adoption of the remaining provisions of
SFAS 157, as amended, did not have a significant impact on our consolidated
financial statements upon adoption, but will impact the accounting for future
acquisitions, including our pending acquisition of Wyeth, and other events and
transactions measured at fair value.
PFIZER
INC. AND SUBSIDIARY COMPANIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
As of
January 1, 2009, we adopted FASB SFAS No. 160, Noncontrolling Interests in
Consolidated Financial Statements, an amendment of Accounting Research
Bulletin No. 51, Consolidated
Financial Statements. SFAS 160 provides guidance for the accounting,
reporting and disclosure of noncontrolling interests, previously referred to as
minority interests. A noncontrolling interest represents the portion of equity
(net assets) in a subsidiary not attributable, directly or indirectly, to a
parent. The adoption of SFAS 160 resulted in a number of changes to the
presentation of our consolidated financial statements, but the amounts
associated with noncontrolling interests are not significant. SFAS 160 could
impact our accounting for future acquisitions where we do not acquire 100% of
the entity and our accounting for the deconsolidations of
subsidiaries.
As of
January 1, 2009, we adopted Emerging Issues Task Force (EITF) Issue No. 07-1,
Accounting for Collaborative
Arrangements. EITF 07-1 provides guidance on: determining whether an
arrangement constitutes a collaborative arrangement within the scope of the
Issue; how costs incurred and revenue generated on sales to third parties should
be reported in the income statement; how an entity should characterize payments
on the income statement; and what participants should disclose in the notes to
the financial statements about a collaborative arrangement. The adoption of EITF
07-1 did not have a significant impact on our consolidated financial statements,
and additional disclosures have been provided. (See Note 4. Collaborative
Arrangements.)
As of
January 1, 2009, we adopted EITF Issue No. 08-3, Accounting by Lessees for
Maintenance Deposits. EITF 08-3 provides guidance that maintenance
deposits paid by a lessee and subsequently refunded only if a lessee fulfills a
maintenance obligation will be accounted for as a deposit asset. The adoption of
EITF 08-3 did not have a significant impact on our consolidated financial
statements.
As of
January 1, 2009, we adopted EITF Issue No. 08-6, Equity Method Investment Accounting
Considerations. EITF 08-6 clarifies how to account for certain
transactions involving equity method investments in areas such as how to
determine the initial carrying value of the investment; how to allocate the
difference between the investor s carrying value and the investor s share of the
underlying equity of the investment; how to perform an impairment assessment of
underlying intangibles held by the investee; how to account for the investee s
issuance of additional shares; and how to account for an investment on the cost
method when it had been previously accounted for under the equity method. The
adoption of EITF 08-6 did not have a significant impact on our consolidated
financial statements, but could impact the accounting for future equity method
investments.
As of
January 1, 2009, we adopted EITF Issue No. 08-7, Accounting for Defensive Intangible
Assets. EITF 08-7 clarifies the accounting for certain separately
identifiable assets, which an acquirer does not intend to actively use but
intends to hold to prevent its competitors from obtaining access to them. EITF
08-7 requires an acquirer to account for a defensive intangible asset as a
separate unit of accounting, which should be amortized to expense over the
period the asset diminishes in value. The adoption of EITF 08-7 did not have a
significant impact on our consolidated financial statements, but could impact
the accounting for future acquisitions.
Note 3.
Acquisitions
In the
first quarter of 2008, we acquired CovX, a privately held biotherapeutics
company specializing in preclinical oncology and metabolic research and the
developer of a biotherapeutics technology platform that we expect will enhance
our biologic portfolio. Also in the first quarter of 2008, we acquired all the
outstanding shares of Coley Pharmaceutical Group, Inc., (Coley), a
biopharmaceutical company specializing in vaccines and drug candidates designed
to fight certain cancers, allergy and asthma disorders, and autoimmune diseases,
for approximately $230 million. In connection with these and two smaller
acquisitions related to Animal Health, we recorded approximately $398 million in
Acquisition-related in-process
research and development charges.
Note 4. Collaborative
Arrangements
In the
normal course of business, we enter into collaborative arrangements with respect
to in-line medicines as well as medicines in development that require completion
of research and regulatory approval. Collaborative arrangements are contractual
agreements with third parties that involve a joint operating activity, typically
a research and/or commercialization effort, where both we and our partner are
active participants in the activity and are exposed to the significant risks and
rewards of the activity. Our rights and obligations under each
collaborative arrangement can vary. For example, we have agreements to
co-promote pharmaceutical products discovered by other companies, and we have
agreements where we partner to co-develop and/or participate together in
commercializing, marketing, promoting, manufacturing, or distributing a drug
product.
PFIZER
INC. AND SUBSIDIARY COMPANIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Payments
to or from our collaboration partners are presented in the statement of income
based on the nature of the arrangement (including its contractual terms), the
nature of the payments and applicable accounting guidance. Under co-promotion
agreements, we record the amounts received from our partners as alliance
revenues, a component of Revenues, when our
co-promotion partners are the principal in the transaction and we receive a
share in their net sales or profits. Alliance revenues are recorded when our
co-promotion partners ship the related product and title passes to their
customer. Expenses for selling and marketing these products are included in
Selling, informational and
administrative expenses. In arrangements where we manufacture product for
our partner, we record revenues when our partner sells the product and title
passes to their customer. All royalty payments to collaboration partners are
recorded as part of Cost of
sales.
The
amounts and classifications of payments (income/(expense)) between us and our
collaboration partners follow:
(millions
of dollars)
First
Quarter
Mar.
29,
2009
Mar.
30,
2008
Revenues
Revenues(a)
132
100
Revenues
Alliance revenues (b)
582
488
Total
Revenues
714
588
Cost
of sales (c)
(56
(31
Selling,
informational and administrative expenses
(17
(7
Research
and development expenses(d)
(194
(50
(a)
Represents
sales to our partners of products manufactured by
us.
(b)
Substantially
all related to amounts earned from our partners under co-promotion
agreements.
(c)
Primarily
related to royalties earned by our partners and cost of sales associated
with inventory purchased from our
partners.
(d)
Primarily
related to net reimbursements earned by our partners except that the first
quarter of 2009 also includes a $150 million milestone payment to one of
our partners.
The
amounts disclosed in the above table do not include transactions with third
parties other than our collaboration partners, or other costs associated with
the products under the collaboration arrangements.
Note 5. Cost-Reduction
Initiatives
We
incurred the following costs in connection with all of our cost-reduction
initiatives which began in 2005:
First
Quarter
(millions
of dollars)
Mar.
29,
2009
Mar.
30,
2008
Implementation
costs(a)
174
357
Restructuring
charges(b)
157
178
Total
costs related to our cost-reduction initiatives
331
535
(a)
For
the first quarter of 2009, included in Cost of sales ($76
million), Selling,
informational and administrative expenses ($46 million), Research and development
expenses ($41 million), and Other (income)/deductions
net ($11 million). For the first quarter of 2008, included in Cost of sales ($138 million), Selling, informational and
administrative expenses ($75 million), Research and development
expenses ($146 million), and Other
(income)/deductions-net ($2 million income).
(b)
Included
in Restructuring charges
and acquisition-related
costs.
From the
beginning of the cost-reduction initiatives in 2005 through March 29, 2009, the
restructuring charges primarily relate to our supply network transformation
efforts and the restructuring of our worldwide marketing and research and
development operations, and the implementation costs primarily relate to
depreciation arising from the shortening of the useful lives of certain assets,
as well as system and process standardization and the expansion of shared
services.
PFIZER
INC. AND SUBSIDIARY COMPANIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
The
components of restructuring charges associated with all of our cost-reduction
initiatives follow:
(millions
of dollars)
Costs
Incurred
Through
Mar.
29,
2009
Activity
Through
Mar.
29,
2009(a)
Accrual
as
of
Mar.
29,
2009(b)
Employee
termination costs
5,285
3,500
1,785
Asset
impairments
1,311
1,311
Other
444
412
32
Total
restructuring charges
7,040
5,223
1,817
(a)
Includes
adjustments for foreign currency translation.
(b)
Included in Other current liabilities
($1.240 billion) and Other noncurrent liabilities
($577
million).
During the
first quarter of 2009, we expensed $135 million for Employee termination costs,
$18 million for Asset
impairments and $4 million for Other. Through March 29,
2009, Employee termination
costs represent the expected reduction of the workforce by approximately
31,000 employees, mainly in manufacturing, sales and research; and approximately
21,400 of these employees have been terminated. Employee termination costs
are recorded when the actions are probable and estimable and include accrued
severance benefits, pension and postretirement benefits. Asset impairments primarily
include charges to write down property, plant and equipment. Other primarily includes
costs to exit certain activities.
Note 6. Acquisition-Related
Costs
We
incurred the following acquisition-related costs in connection with our pending
acquisition of Wyeth:
First
Quarter
(millions
of dollars)
Mar. 29,
2009
Transaction
costs (a)
369
Pre-integration
costs and other(b)
28
Total
acquisition-related costs(c)
397
(a)
Transaction
costs include banking, legal, accounting and other costs directly related
to our pending acquisition of Wyeth. Substantially all of the costs
incurred to date are fees related to our $22.5 billion bridge term loan
credit agreement entered into with financial institutions on March 12,
2009 (see Note 8C.
Financial Instruments: Long-Term Debt) to partially fund our pending
acquisition of Wyeth. Upon our issuance of $13.5 billion of senior
unsecured notes on March 24, 2009, the commitment under the bridge term
loan credit agreement was reduced by an amount equal to the net proceeds
we received from such issuance, to a current balance of $9.1 billion, and,
accordingly, we expensed the portion of the bridge term loan credit
agreement fees associated with the $13.5 billion
reduction.
(b)
Pre-integration
costs represent external, incremental costs directly related to our
pending acquisition of Wyeth and include costs associated with preparing
for systems and other integration
activities.
(c)
Included
in Restructuring charges
and acquisition-related
costs.
PFIZER
INC. AND SUBSIDIARY COMPANIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 7. Comprehensive
Income/(Loss)
The
components of comprehensive income/(loss) follow:
First
Quarter
(millions
of dollars)
Mar.
29,
2009
Mar.
30,
2008
Net
income before allocation to noncontrolling interests
2,730
2,790
Other
comprehensive loss:
Currency translation adjustment
and other
(384
(575
Net unrealized gains/(losses) on
derivative financial instruments
(23
Net unrealized gains/(losses) on
available-for-sale securities
145
(14
Benefit plan
adjustments
159
84
Total other comprehensive
loss
(103
(504
Total
comprehensive income before allocation to noncontrolling
interests
2,627
2,286
Less: Comprehensive income
attributable to noncontrolling interests
Comprehensive
income attributable to Pfizer Inc.
2,625
2,278
Note 8. Financial
Instruments
A. Investments in Debt and
Equity Securities
Investments
in debt securities reflect the investment of proceeds on March 24, 2009, when
Pfizer issued $13.5 billion of senior unsecured notes in anticipation of the
acquisition of Wyeth (see Note
8C. Financial Instruments: Long-Term Debt). The note proceeds were generally
invested in short-term available-for-sale investments such as money market
funds, U.S. Treasury notes, and to a lesser extent, corporate debt.
B. Short-Term
Borrowings
Short-term
borrowings include amounts for commercial paper of $6.1 billion as of March 29,
2009.
As of
March 29, 2009, we had access to $8.2 billion of lines of credit, of which $6.0
billion expire within one year. Of these lines of credit, $8.1 billion are
unused, of which our lenders have committed to loan us $7.1 billion at our
request. $7.0 billion of the unused lines of credit, of which $5.0 billion
expire in the first quarter of 2010 and $2.0 billion expire in 2013, may be used
to support our commercial paper borrowings. The $5.0 billion of lines of credit
expiring in the first quarter of 2010 are subject to substantially the same
credit covenants as the bridge term loan credit agreement noted below. (See
Note 8G. Financial
Instruments: Credit Covenants.)
On March
12, 2009, we entered into a $22.5 billion bridge term loan credit agreement
(bridge credit agreement) in connection with the
pending acquisition of Wyeth. Upon our issuance of $13.5 billion of senior
unsecured notes in March 2009 (see Note 8C. Financial Instruments:
Long-Term Debt), the commitment under
the bridge credit agreement was reduced by an amount equal to the net proceeds
we received from such issuance, to a current balance of $9.1 billion. As of
March 29, 2009, no amounts have been drawn down under the bridge credit
agreement, and borrowings under the bridge credit agreement can only occur on
the consummation date of the Wyeth transaction. Amounts drawn under the bridge
credit agreement must be used to fund a portion of the Wyeth merger
consideration and certain fees and expenses incurred in connection with the
merger and would mature 364 days after the merger consummation date but may be
extended under certain conditions. The loan interest rate is to be calculated at
the highest of specified common base rates, plus specified fixed-rates. The
bridge credit agreement will terminate upon the earliest to occur of the
following: (i) the consummation of merger, (ii) December 31, 2009, (iii) the
abandonment of the merger, (iv) the termination of the merger agreement or (v)
the date on which the commitments under the bridge credit agreement are
cancelled in full. The pending acquisition of Wyeth is expected to occur at the
end of the third quarter or during the fourth quarter of 2009.
Certain
bridge credit agreement fees have been expensed as Acquisition-related costs in
the income statement caption Restructuring charges and
acquisition-related costs (see Note 6.
Acquisition-related costs), while
other bridge credit agreement fees have been deferred and are included in Other assets, deferred taxes and
deferred charges.
10
PFIZER
INC. AND SUBSIDIARY COMPANIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
The bridge
credit agreement subjects us to certain covenants until the commitment expires
and all loans under the agreement, if any, have been paid. (See Note 8G. Financial Instruments:
Credit Covenants.)
C. Long-Term
Debt
On March
24, 2009, as part of our financing of the pending acquisition of Wyeth, we
issued $13.5 billion of senior unsecured notes. Information as of March 29, 2009
is as follows:
(millions
of dollars)
Maturity
Date
2009
Senior
unsecured notes:
Floating rate notes at the
three-month London Interbank
Offering
Rate (LIBOR), plus 1.95%
March
2011
1,250
4.45%(a)
March
2012
3,500
5.35%(a)
March
2015
3,000
6.20%(a)
March
2019
3,250
7.20%(a)
March
2039
2,500
Total
long-term debt issued in connection with the pending acquisition of
Wyeth
13,500
(a)
The
fixed-rate debt is callable at any time at the greater of 100% of the
principal amount or the sum of the present
values of principal and interest discounted at the U.S. Treasury rate,
plus
0.50%.
D. Derivative Financial
Instruments and Hedging Activities
Foreign Exchange Risk - A
significant portion of our revenues, earnings and net investments in foreign
affiliates is exposed to changes in foreign exchange rates. We seek to manage
our foreign exchange risk in part through operational means, including managing
expected same-currency revenues in relation to same-currency costs and
same-currency assets in relation to same-currency liabilities. Depending on
market conditions, foreign exchange risk is also managed through the use of
derivative financial instruments and foreign currency debt. These financial
instruments serve to protect net income and net investments against the impact
of the translation into U.S. dollars of certain foreign-exchange-denominated
transactions. The aggregate notional amount of foreign exchange derivative
financial instruments hedging or offsetting foreign currency exposures is $35
billion. The derivative financial instruments primarily hedge or offset
exposures in euro, Japanese yen, and Swedish kroner.
All
derivative contracts used to manage foreign currency risk are measured at fair
value and are reported as assets or liabilities on the consolidated balance
sheet. Changes in fair value are reported in earnings or deferred, depending on
the nature and purpose of the financial instrument (offset or hedge
relationship) and the effectiveness of the hedge relationships, as
follows:
We
defer on the balance sheet the effective portion of the gains or losses on
foreign currency forward-exchange contracts and foreign currency swaps
that are designated as cash flow hedges and reclassify those amounts, as
appropriate, into earnings in the same
period or periods during which the hedged transaction affects
earnings.
We
recognize the gains and losses on forward-exchange contracts and foreign
currency swaps that are used to offset the same foreign currency assets or
liabilities immediately into earnings along with the earnings impact of
the items they generally offset. These contracts essentially take the
opposite currency position of that reflected in the month-end balance
sheet to counterbalance the effect of any currency
movement.
We
recognize the gains and losses impact on foreign currency swaps designated
as hedges of our net investments in earnings in three ways:
over time for the periodic net swap payments; immediately to the extent of
any change in the difference between the foreign exchange spot rate and
forward rate; and upon sale or substantial liquidation of our net
investments to the extent of change in the foreign exchange spot
rates.
We defer
on the balance sheet foreign exchange gains and losses related to foreign
exchange-denominated debt designated as a hedge of our net investments and
reclassify those amounts into earnings upon the sale or substantial liquidation
of our net investments.
Any
ineffectiveness is recognized immediately into earnings. There was no
significant ineffectiveness in the first quarter of 2009 or the first quarter of
2008.
11
PFIZER
INC. AND SUBSIDIARY COMPANIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Interest Rate Risk - Our
interest-bearing investments, loans and borrowings are subject to interest rate
risk. We invest and loan primarily on a short-term or variable-rate basis;
however, due to the pending acquisition of Wyeth and in light of current market
conditions, we currently borrow primarily on a long-term, fixed-rate basis. From
time to time, depending on market conditions, we will fix interest rates either
through entering into fixed-rate investments or through the use of derivative
financial instruments. The aggregate notional amount of interest rate derivative
financial instruments is $4 billion. The derivative financial instruments
primarily offset euro fixed-rate debt, and to a lesser extent, hedge U.S.
fixed-rate debt.
All
derivative contracts used to manage interest rate risk are measured at fair
value and reported as assets or liabilities on the consolidated balance sheet.
Changes in fair value are reported in earnings, as follows:
We
recognize the gains and losses on interest rate swaps that are designated
as fair value hedges in earnings upon the
recognition of the change in fair value of the hedged risk. We recognize
the offsetting earnings impact of fixed-rate debt attributable to the
hedged risk also in earnings.
Any
ineffectiveness is recognized immediately into earnings. There was no
significant ineffectiveness in the first quarter of 2009 or the first quarter of
2008.
Information
about the fair values of our derivative financial instruments and debt
designated as hedging instruments and the impact on our consolidated balance
sheet follows:
March
29, 2009
Assets
Liabilities
(millions
of dollars)
Balance
Sheet
Location(a)
Fair
Value(b)
Balance
Sheet
Location(a)
Fair
Value (b)
Derivative
financial instruments designated as hedging instruments:
Interest
rate swaps
OCA
OCL
Interest
rate swaps
ONCA
314
ONCL
Foreign
currency swaps
OCA
17
OCL
Foreign
currency swaps
ONCA
143
ONCL
30
Foreign
currency forward-exchange contracts
OCA
276
OCL
266
Total
derivative financial instruments designated as hedging
instruments:
751
311
Derivative
financial instruments not designated as hedging
instruments:
Foreign
currency swaps
ONCA
ONCL
139
Foreign
currency forward-exchange contracts
OCA
233
OCL
650
Total
derivative financial instruments not designated as hedging
instruments
233
789
Total
derivative financial instruments
984
1,100
Nonderivative
financial instruments designated as hedging instruments:
Foreign
currency short-term borrowings
STB
1,273
Foreign
currency long-term debt
LTD
1,927
Total
nonderivative financial instruments designated as hedging
instruments
3,200
(a)
The
primary consolidated balance sheet caption indicates the financial
statement classification of the amount associated with the financial
instrument used to hedge or offset risk. The abbreviations used are
defined as follows: OCA = Taxes and other current
assets; ONCA = Other assets, deferred taxes
and deferred charges; OCL = Other current
liabilities; ONCL = Other noncurrent
liabilities; STB = Short-term
borrowings; and LTD = Long-term
debt.
(b)
See
Note 8E. Financial
Instruments: Fair Value for a description of the valuation
techniques used to determine fair
values.
12
PFIZER
INC. AND SUBSIDIARY COMPANIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Certain of
our derivative instruments have credit-risk-related contingent features designed
to reduce our counterparties exposure to our risk of defaulting on amounts
owed. The aggregate fair value of these derivative instruments that are in a
liability
position is $315 million, for which we have posted collateral of $230 million in
the normal course of business. These features include the requirement to pay
additional collateral in the event of a debt-rating organization ratings
downgrade. If there had been a downgrade to an A rating, or its equivalent, on
March 29, 2009, we would have been required to post an additional $140 million
of collateral to our counterparties. If there had been a downgrade to below an A
rating, or its equivalent, on March 29, 2009, we would have been required to
post an additional $168 million of collateral to our counterparties. (See Note 8F: Financial Instruments: